Introduction {#sec1}
============

Ischemic stroke carries a high mortality and is a leading cause of severe neurological disability. Curative therapeutic options are limited and include intravenous recombinant tissue plasminogen activator and endovascular intervention, whereas cellular therapy has been actively investigated as a new potential treatment for neurological disorders, including ischemic stroke.[@bib1], [@bib2], [@bib3], [@bib4]

A number of pre-clinical and clinical studies have shown that bone marrow mesenchymal stem cell (MSC) transplantation is neuroprotective and improves motor function after cerebral ischemia.[@bib5], [@bib6], [@bib7], [@bib8] In recent MSC-based cell therapy studies for cerebrovascular and cardiovascular diseases, most researchers have emphasized the paracrine action of MSCs rather than their differentiation potential within injured areas.[@bib7], [@bib9] Administered MSCs preferentially migrate into injured brain tissue and can produce therapeutic effects via secretion of growth factors and cytokines, such as brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), and interleukin (IL)-6.[@bib7], [@bib10], [@bib11], [@bib12], [@bib13] In addition, MSCs enhance neuroprotection against cerebral ischemia by upregulating IL-10 expression in peri-ischemic lesion through macrophages, dendritic cells, and peripheral blood mononuclear cells.[@bib14], [@bib15], [@bib16] IL-10 is a pleiotropic anti-inflammatory cytokine mainly produced by type-2 helper T cells, which in turn regulate inflammatory reactions. Specifically, IL-10 inhibits macrophage activation, T cell proliferation, and pro-inflammatory cytokine release, including production of interferon-γ (IFN-γ), IL-2, and tumor necrosis factor alpha (TNF-α) from type-1 helper T cells.[@bib16], [@bib17]

Therapeutic effects of IL-10 administration in experimental stroke models have been reported.[@bib18], [@bib19], [@bib20], [@bib21], [@bib22] IL-10 plays a neuroprotective and vasculoprotective role in the cerebrovascular disorder by attenuating pro-inflammatory signals and upregulating anti-apoptotic proteins, such as B cell lymphoma 2 (Bcl-2) and Bcl-extra large (Bcl-xL).[@bib23], [@bib24] Therefore, we genetically modified MSCs to secrete abundant IL-10 and hypothesized that they may improve MSC-based cell therapy for cerebral ischemia.

In the present study, we investigated the therapeutic benefit of adeno-associated virus (AAV)-mediated IL-10 overexpression in MSCs transplanted during the acute phase of ischemic stroke.

Results {#sec2}
=======

IL-10 Production by IL-10 Gene-Transferred MSCs In Vitro {#sec2.1}
--------------------------------------------------------

IL-10 concentrations in MSC culture supernatant were measured by ELISA. Nontransfected MSCs did not secrete IL-10 protein at either 24 or 72 hr. After transfection with 1 × 10^5^ vector genomes (vg)/cell, MSCs produced IL-10 protein in the supernatant: 59.6 ± 44.5 pg/mL at 24 hr and 1,631.7 ± 450.8 pg/mL at 72 hr ([Figure 1](#fig1){ref-type="fig"}).Figure 1ELISA Quantification of IL-10 In VitroIL-10 concentrations were determined in 24 or 72 hr culture supernatants of IL-10 gene-transferred MSCs. 1 × 10^5^ MSCs were transfected with dsAAV1-CAG-rat IL-10 vg at 0, 0.3, 1, 3, and 10 × 10^5^ per cell. Data are presented as mean ± SD. n = 3 for each group.

Infarct Volumes {#sec2.2}
---------------

There were a total of four experimental groups: MSC-0 hr, transplanted MSCs alone immediately after reperfusion; MSC-3 hr, transplanted MSCs alone at 3 hr after reperfusion; MSC/IL-10-0 hr, transplanted MSC/IL-10 immediately after reperfusion; and MSC/IL-10-3 hr, transplanted MSC/IL-10 at 3 hr after reperfusion. Infarct volumes (mm^3^) were assessed in 2,3,5-tripenyltetrazolium chloride (TTC)-stained sections at 72 hr or 7 days after middle cerebral artery occlusion (MCAO) ([Figures 2](#fig2){ref-type="fig"}A and 2B). At 72 hr after MCAO, infarct volumes in both MSC-0 hr (185.1 ± 26.3, p \< 0.05) and MSC/IL-10-0 hr (117.3 ± 29.5, p \< 0.01) were markedly smaller than vehicle (238.1 ± 37.1). In contrast, MSC/IL-10-3 hr (140.8 ± 54.1, p \< 0.01), but not MSC-3 hr (217.0 ± 18.6), showed a 39% reduction in infarct volume compared with vehicle (232.4 ± 38.9) ([Figure 2](#fig2){ref-type="fig"}C). At 7 days after MCAO, infarct volumes in both MSC-0 hr (180.8 ± 17.8, p \< 0.05) and MSC/IL-10-0 hr (124.7 ± 19.1, p \< 0.01) were also smaller than in vehicle (223.2 ± 22.3). In contrast, MSC/IL-10-3 hr (137.2 ± 22.4, p \< 0.01), but not MSC-3 hr (210.2 ± 17.7), displayed a significant 38% reduction in infarct volume compared with vehicle (222.7 ± 19.5) ([Figure 2](#fig2){ref-type="fig"}D).Figure 2Reduction of Infarct Volumes as Detected by TTC Staining(A and B) Representative photographs showing TTC staining at 72 hr (A) and 7 days (B) after MCAO in vehicle, MSC, or MSC/IL-10-transplanted reperfusion groups at 0 or 3 hr. (C and D) Quantitative analysis of infarct volumes in each group at 72 hr (C) and 7 days (D) after MCAO. Data are presented as mean ± SD (\*p \< 0.05, \*\*p \< 0.01). n = 5 for each group.

Neurological Outcome {#sec2.3}
--------------------

Neurological scores and motor function at 7 days after MCAO are shown ([Figure 3](#fig3){ref-type="fig"}). Both MSC-0 hr and MSC/IL-10-0 hr showed significant improvements in posture score (MSC-0 hr, p \< 0.01; MSC/IL-10-0 hr, p \< 0.01) and palsy score (MSC-0 hr, p \< 0.05; MSC/IL-10-0 hr, p \< 0.01) compared with vehicle. Motor function was also ameliorated in both MSC-0 hr and MSC/IL-10-0 hr compared with vehicle, as assessed by rotarod performance (MSC-0 hr, p \< 0.05; MSC/IL-10-0 hr, p \< 0.01) and forelimb grip strength (MSC-0 hr, p \< 0.05; MSC/IL-10-0 hr, p \< 0.01). However, MSC/IL-10-3 hr, but not MSC-3 hr, showed significant improvements in posture score (p \< 0.01) and hemiparesis score (p \< 0.01) compared with vehicle. MSC/IL-10-3 hr, but not MSC-3 hr, exhibited remarkable recovery in rotarod performance (p \< 0.01) and forelimb grip strength (p \< 0.01) compared with vehicle.Figure 3Improvement of Neurological Score and Motor Function(A and B) Abnormal posture (A) and hemiparesis (B) assessment at 7 days after MCAO in vehicle, MSC, or MSC/IL-10-transplanted reperfusion groups at 0 or 3 hr. Box plots indicate the median and interquartile range, and whiskers indicate the maximum and minimum values (\*p \< 0.05, \*\*p \< 0.01). n = 8 for each group. (C and D) Rotarod performance (C) and forelimb grip strength (D) assessment at 7 days after MCAO in vehicle, MSC, or MSC/IL-10-transplanted reperfusion groups at 0 or 3 hours. Data are presented as mean ± SD (\*p \< 0.05, \*\*p \< 0.01). n = 8 for each group.

Microglial Activation {#sec2.4}
---------------------

Immunohistochemistry staining of ionized calcium binding adaptor molecule 1 (Iba-1) as a marker of microglial activation in the cortical ischemic boundary zone (IBZ) is shown in [Figure 4](#fig4){ref-type="fig"}B. Significantly fewer Iba-1-positive microglia were detected in both MSC-0 hr and MSC/IL-10-0 hr compared with vehicle at 24 hr (MSC-0 hr, p \< 0.05; MSC/IL-10-0 hr, p \< 0.01) and 72 hr (MSC-0 hr, p \< 0.05; MSC/IL-10-0 hr, p \< 0.01) after MCAO. Furthermore, the number of Iba-1-positive microglia in MSC/IL-10-0 hr was markedly lower than in MSC-0 hr at 24 hr (p \< 0.05) and 72 hr (p \< 0.05) after MCAO ([Figure 4](#fig4){ref-type="fig"}C).Figure 4Immunohistochemical Staining for Iba-1 and TNF-α in the Cortical Ischemic Boundary Zone(A) The red-lined square on the brain map shows the cortical ischemic boundary zone. The black area represents the ischemic lesion. (B) Immunohistochemical examination of Iba-1 at 24 and 72 hr after MCAO. Scale bar, 100 μm. (C) Number of immunopositive cells. Data are presented as mean ± SD (\*p \< 0.05, \*\*p \< 0.01). n = 5 for each group. (D) Immunohistochemical examination of TNF-α at 24 and 72 hr after MCAO. Scale bar, 40 μm. (E) Number of immunopositive cells. Data are presented as mean ± SD (\*p \< 0.05, \*\*p \< 0.01). n = 5 for each group.

Pro-inflammatory Cytokine Levels {#sec2.5}
--------------------------------

Immunohistochemistry staining of TNF-α in the cortical IBZ is shown in [Figure 4](#fig4){ref-type="fig"}D. TNF-α-positive cells in both MSC-0 hr and MSC/IL-10-0 hr were significantly fewer than in vehicle at 24 hr (MSC-0 hr, p \< 0.01; MSC/IL-10-0 hr, p \< 0.01) and 72 hr (MSC-0 hr, p \< 0.01; MSC/IL-10-0 hr, p \< 0.01) after MCAO. Furthermore, TNF-α-positive cells in MSC/IL-10-0 hr were fewer than in MSC-0 hr at 24 hr (p \< 0.01) and 72 hr (p \< 0.05) after MCAO ([Figure 4](#fig4){ref-type="fig"}E). TNF-α, IL-1β, and IL-6 levels were also analyzed in brain tissue by ELISA. MSC/IL-10-0 hr markedly suppressed brain tissue TNF-α, IL-1β, and IL-6 levels compared with vehicle (all p \< 0.01 versus vehicle) and MSC-0 hr (p \< 0.05, p \< 0.01, and p \< 0.05 versus vehicle, respectively) ([Figures 5](#fig5){ref-type="fig"}A--5C). Additionally, MSC/IL-10-0 hr significantly suppressed serum TNF-α levels compared with vehicle (p \< 0.01) and MSC-0 hr (p \< 0.05) ([Figure 5](#fig5){ref-type="fig"}D).Figure 5Effect of MSC Transplantation on ELISA expression of TNF-α, IL-1β, and IL-6 in Brain Tissue Extracts or Serum(A--C) Quantification of TNF-α (A), IL-1β (B), and IL-6 (C) expression in ischemic hemisphere extracts at 72 hr after MCAO. (D) Quantification of TNF-α expression in serum at 72 hr after MCAO. Data are presented as mean ± SD (\*p \< 0.05, \*\*p \< 0.01). n = 4 for each group.

Ischemia-Induced Neuronal Damage {#sec2.6}
--------------------------------

Fluoro-Jade C (FJC) staining of neuronal degeneration in the cortical IBZ is shown in [Figure 6](#fig6){ref-type="fig"}A. Significantly fewer FJC-positive cells were detected in both MSC-0 hr and MSC/IL-10-0 hr than in vehicle at 24 hr (MSC-0 hr, p \< 0.05; MSC/IL-10-0 hr, p \< 0.01) and 72 hr (MSC-0 hr, p \< 0.01; MSC/IL-10-0 hr, p \< 0.01) after MCAO. Furthermore, the number of FJC-positive cells in MSC/IL-10-0 hr was markedly lower than in MSC-0 hr at 24 hr (p \< 0.05) and 72 hr (p \< 0.05) after MCAO ([Figure 6](#fig6){ref-type="fig"}B).Figure 6Fluoro-Jade C Staining of Neuronal Degeneration in the Cortical Ischemic Boundary Zone(A) Immunohistochemical examination of Fluoro-Jade C at 24 and 72 hr after MCAO. Scale bar, 100 μm. (B) Number of immunopositive cells. Data are presented as mean ± SD (\*p \< 0.05, \*\*p \< 0.01). n = 5 for each group.

IL-10 Expression in the Ischemic Hemisphere and Serum {#sec2.7}
-----------------------------------------------------

Immunohistochemistry staining of IL-10 in the cortical IBZ is shown in [Figure 7](#fig7){ref-type="fig"}A. The number of IL-10-positive cells in both MSC-0 hr and MSC/IL-10-0 hr was significantly more than in vehicle at 24 hr (MSC-0 hr, p \< 0.01; MSC/IL-10-0 hr, p \< 0.01) and 72 hr (MSC-0 hr, p \< 0.01; MSC/IL-10-0 hr, p \< 0.01) after MCAO. Furthermore, significantly more IL-10-positive cells were detected in MSC/IL-10-0 hr than in MSC-0 hr at 24 hr (p \< 0.01) and 72 hr (p \< 0.01) after MCAO ([Figure 7](#fig7){ref-type="fig"}B). Again, brain tissue IL-10 levels were analyzed by ELISA at 24 and 72 hr after MCAO. In both MSC-0 hr and MSC/IL-10-0 hr, IL-10 levels were markedly increased compared with vehicle at 24 hr (MSC-0 hr, p \< 0.01; MSC/IL-10-0 hr, p \< 0.01) and 72 hr (MSC-0 hr, p \< 0.01; MSC/IL-10-0 hr, p \< 0.01) after MCAO. Furthermore, brain tissue IL-10 levels in MSC/IL-10-0 hr were also higher than in MSC-0 hr at 24 hr (p \< 0.01) and 72 hr (p \< 0.01) after MCAO ([Figure 7](#fig7){ref-type="fig"}C). However, ELISA showed no statistical difference in serum IL-10 levels among groups ([Figure 7](#fig7){ref-type="fig"}D).Figure 7IL-10 Expression in the Ischemic Hemisphere and Serum(A) Immunohistochemical examination of IL-10 at 24 and 72 hr after MCAO. Scale bar, 100 μm. (B) Number of immunopositive cells. Data are presented as mean ± SD (\*p \< 0.05, \*\*p \< 0.01). n = 5 for each group. (C) ELISA quantification of IL-10 expression in the brain at 24 and 72 hr after MCAO. Data are presented as mean ± SD (\*p \< 0.05, \*\*p \< 0.01). n = 4 for each group. (D) ELISA quantification of IL-10 expression in serum at 24 and 72 hr after MCAO. Data are presented as mean ± SD (\*p \< 0.05, \*\*p \< 0.01). n = 4 for each group.

Tracking, Biodistribution, and Quantification of Engrafted MSCs {#sec2.8}
---------------------------------------------------------------

Engrafted MSCs were detected in the ischemic hemisphere by PKH26 labeling and double immunofluorescence analysis. PKH26-labeled cells were detected in both MSC-0 hr and MSC/IL-10-0 hr at 72 hr, whereas none were detected in either group at 14 days after MCAO ([Figure 8](#fig8){ref-type="fig"}A). Merged images showed rat IL-10 expressing MSCs in MSC/IL-10-0 hr at 72 hr after MCAO ([Figure 8](#fig8){ref-type="fig"}B). Biodistribution and quantification of engrafted MSCs using real-time PCR with human-specific Alu sequences is shown in [Figures 8](#fig8){ref-type="fig"}C and 8D. Significantly more human cells were detected in MSC/IL-10-0 hr than in MSC-0 hr at 72 hr and 7 days after MCAO in the ipsilateral hemisphere (72 hr, p \< 0.05; 7 days, p \< 0.05) and spleen (72 hr, p \< 0.05; 7 days, p \< 0.05).Figure 8Tracking, Biodistribution, and Quantification of Engrafted MSCs(A) Tracking of engrafted MSCs and MSC/IL-10 in the ischemic hemisphere by PKH26 labeling at 72 hr and 14 days after MCAO. Fluorescent microscopy detected red fluorescent engrafted cells. Scale bar, 100 μm. (B) Immunofluorescence staining of rat IL-10 (green) and human mitochondria (red) in the ischemic hemisphere of MSC/IL-10-transplanted rats at 72 hr after MCAO. Arrows in the merged image show rat IL-10 expression of engrafted MSC/IL-10. Scale bar, 100 μm. (C and D) Biodistribution and quantification of engrafted MSCs and MSC/IL-10 at 72 hr (C) and 7 days (D) after MCAO using Alu-based real-time PCR. Data are presented as mean ± SD (\*p \< 0.05). n = 4 for each group.

Discussion {#sec3}
==========

Here, we show that overexpressing IL-10 enhances the neuroprotective effect of MSCs and extends the therapeutic time window of MSC transplantation after transient focal ischemia. Cerebral ischemia evokes a strong inflammatory response that is characterized by rapid microglial activation, production of pro-inflammatory mediators, and infiltration of inflammatory cells into injured brain tissue.[@bib25] These reactions play a pivotal role in infarct progression and edema formation in the acute phase of ischemia.[@bib26] IL-10, a key anti-inflammatory cytokine in MSC neuroprotection, suppresses expression of various pro-inflammatory cytokines, such as IFN-γ, IL-1β, IL-2, IL-6, and TNF-α, in the inflammatory environment.[@bib16], [@bib17], [@bib27] In addition, in vitro cell culture studies have shown that IL-10 reduces apoptosis of primary cortical neurons and neurites after oxygen-glucose deprivation through the upregulation of signal transducer and activator of transcription 3 (STAT-3) and phosphatidylinositol 3-kinase (PI3K)/AKT pathways.[@bib28], [@bib29] These pathways mediate neuronal survival and neurite growth by modulating expression of the antiapoptotic proteins Bcl-2 and Bcl-xL.[@bib23], [@bib30], [@bib31] Here, as expected, IL-10-overexpressing MSCs significantly reduced infarct volume and enhanced motor functional recovery at 72 hr and 7 days after MCAO. Further, ELISA showed that MSC/IL-10 transplantation after ischemic stroke led to higher IL-10 levels and lower pro-inflammatory cytokine (TNF-α, IL-1β, and IL-6) levels in ischemic brain tissue. Moreover, MSC/IL-10 transplantation elevated IL-10 levels in the ischemic hemisphere without affecting serum IL-10 levels, thereby likely decreasing the risk of systemic IL-10-induced adverse reactions, such as anemia, thrombocytopenia, and immunosuppression.[@bib22], [@bib32] MSC/IL-10 transplantation also significantly reduced neuronal damage in the cortical IBZ.

We performed heterologous transplantation of human MSCs into the rat tail vein. Intravenous administration of MSCs is minimally invasive and an effective and safe procedure for stroke patients.[@bib33], [@bib34], [@bib35] Recent studies have shown that engrafted human MSCs survive in damaged CNS tissue for a few weeks and exert neuroprotective and immunomodulatory effects in human/rat xenotransplantation models without immunosuppressive drugs.[@bib36], [@bib37] We detected intravenously transplanted MSC/IL-10 and non-genetically modified MSCs in the ischemic hemisphere at 72 hr, which disappeared at 14 days after MCAO. Furthermore, we investigated biodistribution and the relative number of engrafted MSCs and MSC/IL-10 using human-specific Alu-based real-time PCR as an established method to detect human DNA in mixed samples from other species.[@bib38] Compared with non-genetically modified MSCs, higher numbers of engrafted MSC/IL-10 were detected in the ischemic hemisphere and spleen at 72 hr and 7 days after MCAO. These results indicate that overexpressing IL-10 may improve engrafted MSC survival in the injured brain and spleen. The spleen is known to be associated with systemic inflammatory stroke responses via pro-inflammatory cytokines and chemokine production by splenic lymphocytes, macrophages, and neutrophils.[@bib39] Here, ELISA showed that MSC/IL-10 transplantation suppressed serum TNF-α levels as a marker of systemic inflammation. Thus, our results suggest that systemic delivery of MSC/IL-10 may enhance the systemic anti-inflammatory effects of MSCs by greater accumulation, not only in the ischemic hemisphere, but also in the spleen.

We used the AAV vector to transfer the rat IL-10 gene into human MSCs. The AAV vector is derived from a non-pathogenic human virus belonging to the parvovirus family and can transduce non-dividing cells and achieve long-term gene expression in vivo, with minimal immune responses.[@bib40] Despite its most frequent use for gene therapy, the AAV vector has the potential risk of cytotoxicity and viral DNA integration into the host genome.[@bib41], [@bib42] Although administration of an AAV vector encoding rat IL-10 is reportedly neuroprotective against cerebral ischemia, neutralizing AAV antibodies are found in 20%--40% of adult humans and some animal species.[@bib22], [@bib43] In the presence of neutralizing AAV antibodies, more than double the amount of the AAV vector is needed. Random integration of AAV DNA into the host genome occurs at a very low frequency, but gene therapy using a large amount of AAV vector may cause integration of AAV DNA into the host genome. Risk of AAV DNA integration might be avoided by transferring the AAV vector into MSCs instead of direct AAV vector administration.

We found that IL-10 gene transfer extended the ischemic therapeutic time window of MSC transplantation from 0 to 3 hr after ischemia reperfusion. In contrast, recent studies using rat models reported that MSC administration after more than 24 hr of ischemia reperfusion improved motor function recovery in the subacute phase of ischemic stroke.[@bib5], [@bib6], [@bib7], [@bib10] Further studies are needed to investigate the therapeutic time window of MSC/IL-10 transplantation after cerebral ischemia and evaluate neurological deficits at the subacute and chronic stages of stroke.

In conclusion, our study suggests that IL-10 gene transfer is desirable to enhance the neuroprotective effects of MSC transplantation during the acute phase of ischemic stroke by suppression of the neuroinflammatory reaction and promotion of host neuronal survival. Combined therapy of AAV-induced IL-10 gene expression and MSC transplantation may be safer than direct IL-10 gene transfer with the AAV vector and be clinically applied for stroke therapy in the future.

Materials and Methods {#sec4}
=====================

Plasmid and Vector Construction {#sec4.1}
-------------------------------

The recombinant double-strand AAV vector plasmid pdsAAV-CBA-EGFP was a kind gift from Arun Srivastava (University of Florida College of Medicine). pdsAAV-CAG-EGFP was generated by replacing the chicken beta-actin (CBA) promoter region of pdsAAV-CBA-EGFP with the cytomegalovirus immediate-early enhancer/chicken β-actin hybrid (CAG) promoter region, as previously described.[@bib44] Using the In-Fusion HD Cloning Kit (TakaRa Bio), the EGFP region of pdsAAV-CAG-EGFP was replaced with rat IL-10 to generate pdsAAV-CAG-IL-10: rat IL-10 driven by the CAG promoter. Rat IL-10 was PCR cloned from rat splenocyte cDNA, as previously described.[@bib24] Recombinant dsAAV vectors (dsAAV1-CAG-IL-10) were generated from cultured serum-free medium using polyethylenimine-based triple transfections of HEK293 cells.[@bib45] AAV vector titer was determined by real-time PCR using a 7500 Fast Real-Time Instrument (Applied Biosystems) with rat IL-10 gene primers: forward, 5′-TAAGCTCCAAGACAAAGGGTG-3′; and reverse, 5′-GTCCTCCAGTCCAGTAGATG-3′.

Cell Preparation {#sec4.2}
----------------

Human bone-marrow-derived MSCs were manufactured by JCR Pharmaceuticals. MSCs were cultured at 37°C in 98% humidity and 5% CO~2~. The culture medium was DMEM (Gibco-BRL) supplemented with 10% fetal bovine serum (FBS) (Gibco-BRL), 1% antibiotic-antimyocotic (Wako), and 50 μg/mL ascorbic acid 2-phosphate (Wako).

Ex Vivo Gene Delivery to MSCs {#sec4.3}
-----------------------------

Second to fourth passage cultured MSCs were placed in each well of a six-well dish (1 × 10^6^ cells). Cells were infected with a viral suspension of 1 × 10^5^ vg/cell, and incubated in FBS-free medium 24 hr before transplantation.

Transient MCAO Model {#sec4.4}
--------------------

All experimental procedures were performed according to guidelines approved by the Nippon Medical School Animal Ethics Committee. Male Sprague-Dawley rats (8 weeks; 250--300 g) purchased from Sankyo Labo Service were used. Rats were fasted overnight before and after surgery and had free access to tap water. Anesthesia was initially induced with 5% halothane, and then maintained with 1% halothane in a mixture of 70% N~2~O and 30% O~2~ under spontaneous breathing. A polyethylene PE-50 catheter was inserted into the tail artery to monitor the arterial blood gas condition, blood glucose, and mean arterial blood pressure. Levels were measured immediately before, during, and after ischemia. Rats were subjected to 90 min MCAO using an intraluminal suture technique.[@bib46] Briefly, the left common, internal carotid, and external carotid arteries were carefully exposed through a midline incision. The common and external carotid arteries were double ligated using 4-0 silk sutures. Focal cerebral ischemia was induced by insertion of a silicone rubber-coated 4-0 nylon thread through the left internal carotid artery for 90 min. Reperfusion was achieved by withdrawing the thread. Temporal muscle temperature was maintained at 37°C ± 0.5°C during the procedure.

Intravenous Transplantation of MSCs {#sec4.5}
-----------------------------------

A PE-50 catheter was inserted into the tail vein during ischemia. MSCs (1 × 10^6^ in 1 mL of PBS), MSC/IL-10 (1 × 10^6^ in 1 mL of PBS), or vehicle (1 mL of PBS) was intravenously injected through the catheter at 0 or 3 hr after ischemia reperfusion. No immunosuppressive drugs were used.

Experimental Groups {#sec4.6}
-------------------

There were four experimental groups: MSC-0 hr, transplanted MSCs alone immediately after reperfusion; MSC-3 hr, transplanted MSCs alone at 3 hr after reperfusion; MSC/IL-10-0 hr, transplanted MSC/IL-10 immediately after reperfusion; and MSC/IL-10-3 hr, transplanted MSC/IL-10 at 3 hr after reperfusion.

Measurement of Infarct Volumes {#sec4.7}
------------------------------

To measure infarct volumes, rats were decapitated at 72 hr or 7 days after MCAO (n = 5 for each group). Brains were cut into 2-mm-thick coronal sections and stained with TTC (Wako). Infarct areas were separately determined using ImageJ (NIH). Infarct volumes were calculated by adding total infarct areas.

Behavioral Tests {#sec4.8}
----------------

Neurological symptoms were assessed at 7 days after MCAO by an observer blinded to the study protocol. Hemiparesis and abnormal posture were evaluated using the previously described scoring system.[@bib47] The right hind limb of each rat was gently extended with a round-tipped forceps, and the flexor response was scored as 0, normal; 1, slight deficit; 2, moderate deficit; or 3, severe deficit. For assessment posture, rats were suspended by the tail, and forelimb flexion and body twisting was scored as 0, normal; 1, slight twisting; 2, marked twisting; or 3, marked twisting and forelimb flexion. The rotarod test was performed using a rotarod device (Model 7750; Ugo Basile) to examine locomotor coordination ability. Rotating speed of the rod was started at 4 rpm and accelerated to 40 rpm over 5 min with an increase in speed every 30 s. The average reading (in seconds) of three successive trials was obtained for each rat. Preoperative rats that repeatedly fell were placed back onto the rod until they could balance for 150 s. Forelimb grip strength was determined using a grip strength meter (Chatillon DFIS-10; Ametek). The average reading (in newtons) of three successive trials was obtained for each rat.

Immunohistochemistry {#sec4.9}
--------------------

At 24 or 72 hr after MCAO, rats were deeply anesthetized and transcardially perfused with heparinized saline followed by 4% paraformaldehyde in PBS (n = 5 for each group). Brains were rapidly removed and coronal cryosections (20 μm) were cut. Briefly, sample sections were incubated with 10% goat serum in PBS to block nonspecific reactions, followed by overnight incubation at 4°C with rabbit polyclonal antibodies against Iba-1 (1:500, Wako), rabbit polyclonal antibody against TNF-α (1:100, Abbiotec), or rabbit polyclonal antibody against IL-10 (1:100, Bioss). Next, sections were processed with biotinylated goat anti-polyvalent (Thermo Fisher Scientific) at room temperature for 1 hr, followed by avidin-biotin-peroxidase complex (Vector Laboratories) for 30 min. Labeled secondary antibodies were visualized using diaminobenzidine. Each process was followed by several brief PBS washes. Immunopositive cells in the cortical IBZ were counted in three randomly chosen square fields (0.5 mm^2^). To determine the effect of each treatment upon neuronal degeneration, FJC staining was performed according to manufacturer protocols using a commercially available kit (FJC Ready-to-Dilute Staining Kit for Identifying Degenerating Neurons; Biosensis). Positively stained cells in 0.5 mm^2^ regions in the IBZ adjacent to the ischemic core were counted using a microscope (Eclipse E500W; Nikon) by an investigator blinded to the experimental groups.

ELISA {#sec4.10}
-----

Concentration of IL-10 in brain tissue extracts from the ischemic hemisphere, serum, and culture supernatant were measured using an ELISA kit (R&D Systems) according to the manufacturer's instructions. Concentrations of TNF-α, IL-1β, and IL-6 in brain tissue extracts or serum were also measured by ELISA kits (R&D Systems). Colorimetric absorbance was recorded at a wavelength of 450 nm.

PKH26 Labeling and Immunofluorescent Staining {#sec4.11}
---------------------------------------------

A PKH26 red fluorescent cell linker kit (Sigma-Aldrich) was used to detect engrafted MSCs and MSC/IL-10. Rats injected with PKH26-labeled MSCs or MSC/IL-10 were decapitated at 72 hr or 14 days after MCAO. Frozen brains were cut into 20-μm cryostat sections. For identification of IL-10 secreting MSC/IL-10, brain sections (20 μm) from MSC/IL-10-transplanted rats at 72 hr after MCAO were incubated overnight at 4°C with rabbit polyclonal antibody against IL-10 (1:50) and mouse polyclonal antibody against human mitochondria (1:800, Abcam). Alexa 488 goat anti-rabbit (1:250) or Alexa 568 goat anti-mouse (1:250) (Invitrogen-Life Technologies) was used as the secondary antibody. Sections were protected from light and incubated with secondary antibodies for 1 hr at room temperature. Sections of PKH26-labeled or immunofluorescent-stained samples were mounted using Vectashield (mounting medium for fluorescence) with DAPI (Vector Laboratories). Fluorescent images were captured using a microscope at 200 × magnification (Eclipse E500W; Nikon).

Alu-Based Real-Time PCR {#sec4.12}
-----------------------

Biodistribution and relative amount of engrafted MSCs were determined using Alu-based real-time PCR. Genomic DNA was prepared from the brain, spleen, lungs, and femoral bone marrow of MSC-transplanted rats using the QIAamp DNA mini kit (QIAGEN). To quantify the amount of human DNA from engrafted MSCs, real-time PCR was performed using human-specific Alu sequence primers: forward, 5′-GTCAGGAGATCGAGACCATCCC-3′; and reverse, 5′-TCCTGCCTCAGCCTCCCAAG-3′. Real-time PCR was performed in 1-μL volumes containing 0.5 μM each primer, 25 μL of SYBER premix Ex Taq (2 ×) (Takara Bio), and 5-μL sample DNA (final 20 ng/μL) using an ABI 7500 System (Applied Biosystems). The PCR protocol consisted of 2 min of denaturation at 95°C, followed by 40 cycles of 95°C for 15 s, 68°C for 30 s, and 72°C for 30 s. To determine the diploid chromosome count of each sample, a housekeeping gene was used, rat glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primers for rat GAPDH were forward, 5′-CAACGACCCCTTCATTGACC-3′; and reverse, 5′-GAAGACGCCAGTAGACTCCA-3′. In each sample, the average cell number of engrafted MSCs per diploid was determined.

Statistical Analysis {#sec4.13}
--------------------

Data represent mean ± SD. One-way ANOVA followed by the post hoc Tukey honest significant difference (HSD) test was used for comparisons of infarct volumes, rotarod test balance time, forelimb grip strength, immunohistochemical cell counts, and ELISA data. To compare neurological scores, the Wilcoxon rank-sum test was used. Student's t test was performed to examine real-time PCR data. Differences were considered significant at p \< 0.05. JMP9 software (SAS Institute) was used for all statistical analysis.
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